NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback